Action AZN ASTRAZENECA PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Marché Fermé - London S.E.
Autres places de cotation
 17:35:29 06/06/2024 		Varia. 5j. Varia. 1 janv.
12 590 GBX +0,59 % Graphique intraday de AstraZeneca PLC +4,67 % +18,77 %
05/06 ASTRAZENECA PLC : HSBC toujours positif ZM
05/06 Le ministère de la Santé d'Abou Dhabi et AstraZeneca élargissent leur partenariat lors de la BIO International Convention 2024 pour créer un nouveau centre d'excellence pour les maladies rares CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'
AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal
AQ
AstraZeneca - Acquisition of Fusion completed
AQ
AstraZeneca : Biographies
PU
AstraZeneca : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K
PU
AstraZeneca : Transparency Directive - Form 6-K
PU
AstraZeneca immunotherapy could boost lung cancer survival
AQ
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K
PU
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
PU
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa
AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension
AQ
Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux
BU
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
BU
Astrazeneca looks to double revenue in 'new era of growth'
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AZN
  4. Actualités AstraZeneca PLC
  5. Communiqués
-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT